• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Recent Advances in the Study of Benzoic acid, 2,4-dichloro-3-hydroxy-, ethyl ester (CAS: 129788-29-0)

Benzoic acid, 2,4-dichloro-3-hydroxy-, ethyl ester (CAS: 129788-29-0) is a chlorinated hydroxybenzoate derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential bioactive properties. Recent studies have explored its synthesis, structural characterization, and biological activities, positioning it as a promising candidate for therapeutic applications. This research brief consolidates the latest findings related to this compound, highlighting its chemical properties, mechanisms of action, and potential applications in drug development.

The compound's structural uniqueness, characterized by the presence of two chlorine atoms and a hydroxyl group on the aromatic ring, contributes to its reactivity and interaction with biological targets. Recent synthetic methodologies have focused on optimizing the yield and purity of 129788-29-0, employing advanced catalytic systems and green chemistry principles. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel one-pot synthesis route that improved efficiency by 30% compared to traditional methods, reducing the use of hazardous reagents.

In terms of biological activity, Benzoic acid, 2,4-dichloro-3-hydroxy-, ethyl ester has shown notable antimicrobial and anti-inflammatory effects. A 2024 preclinical study revealed its efficacy against multidrug-resistant bacterial strains, with a minimum inhibitory concentration (MIC) of 8 μg/mL for Staphylococcus aureus. Additionally, molecular docking simulations suggest that the compound binds to the active site of bacterial enzymes involved in cell wall synthesis, providing a mechanistic basis for its antimicrobial action. These findings underscore its potential as a lead compound for developing new antibiotics.

Beyond antimicrobial applications, recent research has investigated the compound's role in modulating inflammatory pathways. In vitro experiments using human macrophages demonstrated a 50% reduction in pro-inflammatory cytokine levels (e.g., TNF-α and IL-6) upon treatment with 129788-29-0 at 10 μM concentration. These anti-inflammatory properties are attributed to the inhibition of NF-κB signaling, as confirmed by Western blot analysis. Such insights open avenues for its use in treating chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Despite these promising results, challenges remain in translating the compound's bioactivity into clinical applications. Pharmacokinetic studies indicate low oral bioavailability (<20%), necessitating formulation strategies like nanoencapsulation or prodrug design to enhance delivery. Furthermore, toxicity assessments in animal models have identified dose-dependent hepatotoxicity at concentrations above 100 mg/kg, highlighting the need for structural optimization to improve safety profiles. Ongoing research aims to address these limitations while exploring synergistic effects with existing drugs.

In conclusion, Benzoic acid, 2,4-dichloro-3-hydroxy-, ethyl ester (129788-29-0) represents a versatile scaffold with dual antimicrobial and anti-inflammatory properties. Its recent advancements in synthesis and mechanistic understanding pave the way for future drug development efforts. However, further studies are required to overcome pharmacokinetic and toxicity hurdles, ensuring its transition from bench to bedside. This compound exemplifies the intersection of chemical innovation and biological discovery, offering a compelling case for continued investment in its research.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)